The iCAN trial is a pragmatic randomized controlled trial investigating whether high-flow nasal cannula oxygen therapy (HFNC) reduces the risk of reintubation in high-risk cardiac surgery patients. The study enrolls 3568 participants and aims to determine if HFNC, delivered via a heated and humidified system allowing for prescribed fraction of inspired oxygen (FIO2) levels at high flow rates, decreases the all-cause reintubation rate within 48 hours of initial extubation.
Study Design and Methodology
Participants will be randomized to receive either a physician order set recommending HFNC or a provider choice of usual care order sets. HFNC is routinely employed by providers in the cardiovascular intensive care unit alongside therapies such as bi-level positive airway pressure and non-rebreather masks. Currently, there is no high-quality clinical data demonstrating that HFNC may decrease the risk of reintubation in this critically-ill adult population. The trial will compare HFNC to usual care, with randomization occurring at the time the patient is deemed ready for extubation by the attending physician in the cardiovascular intensive care unit. Data collection regarding reintubation and outcomes will continue until patient discharge. The study’s design is prospective and clinical.